Dr Bob Terbrueggen
Bob Terbrueggen, PhD, is the Founder and CEO of DxTerity Diagnostics, a Los Angeles based diagnostics company and clinical laboratory. DxTerity specializes in developing gene expression based diagnostic tests for immune health monitoring with active programs in Lupus, Lymphoma, and Radiation Exposure. Bob was principal investigator on multiple radiation diagnostic development contracts funded by the BARDA, a division of the US government’s Health and Human Services, and DxTerity has more than 25 active clinical trials on-going with 11 different pharmaceutical companies.
Bob has a BS in Chemistry and Molecular Biology from the University of Michigan, and a PhD in Chemistry from the California Institute of Technology. He is an inventor on 26 issued US patents and more than 100 international patents.